

## Literatura ACTA MEDICINAE 1/2023 Biologická a cílená léčba

- 3 **Konjugáty protilátky a léčiva v léčbě HER2 pozitivního a HER2 low karcinomu prsu**  
prof. MUDr. Petra Tesařová, CSc. Ústav radiační onkologie FNB a 1. LF UK a Onkologická klinika VFN a 1. LF UK, Praha
- 3 **Současné místo trastuzumab deruxtecanu v léčbě karcinomu žaludku a gastroezofageální jankce**  
doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika, 1. LF UK a VFN v Praze
- 3 **Novinky v léčbě karcinomu ledvin**  
prof. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 2. LF UK a FN v Motole, Praha
- 3 **Imunoterapie v léčbě zhoubných nádorů hlavy a krku v ČR**  
MUDr. Lucie Pavelková | MUDr. Markéta Bonaventurová | prof. MUDr. Jan Plzák, Ph.D.  
Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN v Motole, Praha
- 4 **Pětiletý update celkového přežití ve studiích s imuno-onkoterapií u nemalobuněčného karcinomu plic**  
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 4 **CAR-T lymfocyty v terapii ne Hodgkinských lymfomů**  
MUDr. Kamila Polgárová, Ph.D. | MUDr. Tereza Líkařová | prof. MUDr. Marek Trněný, CSc.  
I. interní klinika – klinika hematologie VFN v Praze a 1. LF UK, Praha
- 5 **Polatuzumab vedotin v léčbě agresivních lymfomů**  
MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – hematologie, 1. LF UK a VFN v Praze
- 5 **Můžeme myelom zcela vyléčit? Daratumumab, elotuzumab a isatuximab v léčbě mnohočetného myelomu**  
MUDr. František Sedlák I. interní klinika – klinika hematologie, 1. LF UK a VFN v Praze
- 6 **Přehled aktuálních doporučení a hlavních směrů v terapii chronické lymfocytární leukemie**  
MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie, Všeobecná fakultní nemocnice a 1. LF UK, Praha
- 6 **Terapeutické možnosti blokady komplementu v léčbě atypického hemolyticko-uremického syndromu**  
prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a VFN v Praze
- 7 **Biologická léčba u nemocných s AL amyloidózou**  
prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a Všeobecná fakultní nemocnice v Praze  
MUDr. Tomáš Pika, Ph.D. Hemato-onkologická klinika, LF UP a FN Olomouc
- 7 **Update systémové léčby atopického ekzému podle EuroGuiDerm – reportáž**
- 7 **Perioperační úpravy antirevmatické léčby**  
MUDr. Liliana Šedová | MUDr. Jana Tomasová-Studýnková, Ph.D. Revmatologický ústav, Praha
- 7 **Terapie komplikované psoriatické artritidy inhibítorem IL-17 – kazuistika**  
MUDr. Jan Tomš, Ph.D. II. interní gastroenterologická klinika LF UK a FN Hradec Králové
- 8 **Switch pacienta s Crohnovou nemocí z i. v. infliximabu na s. c. z důvodu positivity protilátek proti infliximabu – kazuistika**  
MUDr. Iva Lerchová Centrum biologické terapie, Městská nemocnice Ostrava
- 8 **Subkutánně aplikovaný infliximab, řešení při špatném žilním přístupu – kazuistika**  
MUDr. Vladimír Kojecký, Ph.D. Interní oddělení, Krajská nemocnice T. Bati, Zlín
- 8 **Postavení upadacitinibu v léčbě idiopatických střevních zánětů**  
prof. MUDr. Milan Lukáš, CSc., AGAF Klinické a výzkumné centrum pro idiopatické střevní záněty, Klinické centrum ISCARE, a. s., a 1. LF UK, Praha
- 8 **Jak zlepšit dostupnost a výsledky léčby revmatoidní artritidy biologickými léky**  
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 8 **Postup v léčbě pacientů s revmatoidní artritidou a nedostatečnou odpovědí na první anti-TNF léčbu**  
doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 9 **Únava – závažný a nedoceněný projev revmatických onemocnění**  
doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie LF a FN Hradec Králové

- 9 **Certolizumab pegol ve vztahu k akutní přední uveitidě. Výsledky studie C-VIEW**  
MUDr. Kristýna Bubová, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 9 **Postavení adalimumabu v léčbě revmatických chorob**  
prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha
- 10 **Bolest a její ovlivnění u spondyloartritid**  
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie, Fakultní nemocnice v Plzni
- 10 **Pacient s těžkou formou alopecia areata dosahuje rychlého růstu vlasů po léčbě baricitinibem – kazuistika**  
MUDr. PharmDr. Athanasios J. Stefanis Dermatovenerologická klinika 3. LF UK a Fakultní nemocnice Královské Vinohrady, Praha
- 10 **Přehled současných možností léčby roztroušené sklerózy**  
MUDr. Radek Ampapa Centrum pro léčbu demyelinizačních onemocnění, Neurologické oddělení Nemocnice Jihlava
- 10 **Biologická léčba astmatu**  
MUDr. Alena Vlachová | doc. MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 11 **Současné možnosti léčby autozomálně dominantní polycystické choroby ledvin**  
doc. MUDr. Jana Reiterová, Ph.D. Klinika nefrologie 1. LF UK a VFN v Praze

# Konjugáty protilátky a léčiva v léčbě HER2 pozitivního a HER2 low karcinomu prsu

prof. MUDr. Petra Tesařová, CSc. Ústav radiační onkologie FNB a 1. LF UK a Onkologická klinika VFN a 1. LF UK, Praha

- 1 Thomas, A. – Teicher, B. A. – Hassan, R.: Antibody-drug conjugates for cancer therapy. *Lancet Oncol*, 2016, 17, s. e254–e262.
- 2 Barroso-Sousa, R. – Tolaney, S. M.: Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond. *Bio Drugs*, 2021, 35, s. 159–174.
- 3 Staudacher, A. H. – Brown, M. P.: Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? *Br J Cancer*, 2017, 117, s. 1736–1742.
- 4 Li, L. – Zhang, D. – Liu, B., et al.: Konjugáty protilátek a léčiv v HER2-positivním karcinomu prsu. *Chin Med J*, 2022, 135, s. 261–267.
- 5 Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*, 2001, 344, s. 783–792.
- 6 Chau, C. H. – Steeg, P. S. – Figg, W. D.: Antibody-drug conjugates for cancer. *Lancet*, 2019, 394, s. 793–804.
- 7 Krop, I. E. – Kim, S. B. – González-Martín, A., et al.: Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 689–699.
- 8 Modi, S. – Saura, C. – Yamashita, T., et al.: Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. *Cancer Res*, 2021, 81, s. PD3-06.
- 9 Modi, S. – Park, H. – Murthy, R. K., et al.: Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. *J Clin Oncol*, 2020, 38, s. 1887–1896.
- 10 Birrer, M. J. – Moore, K. N. – Betella, I., et al.: Antibody-drug conjugate-based therapeutics: state of the science. *J Natl Cancer Inst*, 2019, 111, s. 538–549.
- 11 Verma, S. – Miles, D. – Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*, 2012, 367, s. 1783–1791.
- 12 von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med*, 2019, 380, s. 617–628.
- 13 Hurvitz, S. A. – Martin, M. – Jung, K. H., et al.: Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. *J Clin Oncol*, 2019, 37, s. 2206–2216.
- 14 Lee, J. – Park, Y. H.: Trastuzumab deruxtecan for HER2+ advanced breast cancer. *Future Oncol*, 2022, 18, s. 7–19.
- 15 Perez, J. – Garrigós, L. – Gion, M., et al.: Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. *Expert Opin Biol Ther*, 2021, 21, s. 811–824.
- 16 Makhlin, I. – DeMichele, A.: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. *Cell Rep Med*, 2022, 3, s. 100668.
- 17 Modi, S. – Jacot, W. – Yamashita, T., et al.: DESTINY-Breast04 Trial Investigators: Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. *N Engl J Med*, 2022, 387, s. 9–20.
- 18 Banerji, U. – van Herpen, C. M. L. – Saura, C., et al.: Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. *Lancet Oncol*, 2019, 20, s. 1124–1135.
- 19 Saura Manich, C. – O'Shaughnessy, J. – Aftimos, P. G., et al.: LBA15 – Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. ESMO Congress 2021. *Ann Oncol*, 2021, 32, suppl. 5, s. S1283–S1346, 10.1016/annonc/annonc741.
- 20 Bianchini, G. – Arpino, G. – Biganzoli, L., et al.: Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an Italian Expert Panel. *Cancers*, 2022, 14, s. 1022.
- 21 Bartsch, R. – Berghoff, A. S. – Furtner, J., et al.: Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. *Nat Med*, 2022, 28, s. 1840–1847.
- 22 Harbeck, N., et al.: A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early breast cancer (DESTINY-Breast11). 2021 San Antonio Breast Cancer Symposium. Abstrakt OT1-12-04. Prezentováno 8. 12. 2021.
- 23 Ferraro, E. – Drago, J. Z. – Modi, S.: Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. *Breast Cancer Res*, 2021, 23, s. 84.
- 24 Khongorzul, P. – Ling, C. J. – Khan, F. U., et al.: Antibody-drug conjugates: a comprehensive review. *Mol Cancer Res*, 2020, 18, s. 3–19.

# Současné místo trastuzumab deruxtecanu v léčbě karcinomu žaludku a gastroezofageální junkce

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika, 1. LF UK a VFN v Praze

- 1 Krejčí, D. – Pehalová, L. – Talábová, A., et al.: Rozvoj technologické platformy NZIS. Novotvary 2018 ČR. Zhubný novotvar žaludku (C16). Dostupné z: <https://www.uzis.cz/res/f/008352/novotvary2018.pdf>, s. 78–87, vyhledáno 14. 2. 2023.
- 2 Dostupné z: [www.svod.cz](http://www.svod.cz).
- 3 Wagner, A. D. – Grothe, W. – Haerting, J., et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol*, 2006, 24, s. 2903–2909.
- 4 Kang, Y. K. – Boku, N. – Satoh, T., et al.: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2017, 390, s. 2461–2471.
- 5 Janjigian, Y. Y. – Shitara, K. – Moehler, M., et al.: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*, 2021, 398, s. 27–40.
- 6 Sun, J. M. – Shen, L. – Shah, M. A., et al.: KEYNOTE-590 Investigators: Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. *Lancet*, 2021, 398, s. 759–771.
- 7 Chao, J. – Fuchs, C. S. – Shitara, K., et al.: Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. *JAMA Oncol*, 2021, 7, s. 895–902.
- 8 Fuchs, C. S. – Özgüroğlu, M. – Bang, Y. J., et al.: Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. *Gastric Cancer*, 2022, 25, s. 197–206.
- 9 Bang, Y. J. – Van Cutsem, E. – Feyereislova, A., et al.: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet*, 2010, 376, s. 687–697.
- 10 Li, X. – Xu, J. – Xie, J., et al.: Research progress in targeted therapy and immunotherapy for gastric cancer. *Chin Med J*, 2022, 135, s. 1299–1313.
- 11 Janjigian, Y. Y. – Kawazoe, A. – Yañez, P., et al.: The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. *Nature*, 2021, 600, s. 727–730.
- 12 Thuss-Patience, P. C. – Shah, M. A. – Ohtsu, A., et al.: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *Lancet Oncol*, 2017, 18, s. 640–653.
- 13 Shitara, K. – Bang, Y.-J. – Iwasa, S., et al.: Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med*, 2020, 382, s. 2419–2430.
- 14 Helwick, C.: DESTINY-Gastric02: Fam-trastuzumab deruxtecan-nxki produces responses in patients with HER2-positive gastric cancers. 2021. Dostupné z: <https://ascopost.com/news/september-2021/destiny-gastric02-trastuzumab-deruxtecan-produces-responses-in-patients-with-her2-positive-gastric-cancers/>, vyhledáno 14. 2. 2023.

# Novinky v léčbě karcinomu ledvin

prof. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 2. LF UK a FN v Motole, Praha

- 1 Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhubných nádorů v České republice. Masarykova univerzita. Dostupné z: <http://www.svod.cz>, vyhledáno 3. 2. 2023.
- 2 Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med*, 2021, 385, s. 683–694.
- 3 Tran, J. – Ornstein, M. C.: Clinical review on the management of metastatic renal cell carcinoma. *JCO Oncol Pract*, 2022, 18, s. 187–196.
- 4 Bex, A. – Haanen, J.: Do targeted agents offer clinical benefit as pre-surgical therapy? *World J Urol*, 2014, 32, s. 3–8.
- 5 Matrana, M. R. – Baiomy, A. – Campbell, M., et al.: Outcomes of patients with metastatic non-clear-cell renal cell carcinoma treated with pazopanib. *Clin Genitourin Cancer*, 2017, 15, s. e205–e208.
- 6 Modrá kniha ČOS. Česká onkologická společnost, 2022. MOU Brno. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 14. 2. 2023.

# Imunoterapie v léčbě zhubných nádorů hlavy a krku v ČR

MUDr. Lucie Pavelková | MUDr. Markéta Bonaventurová | prof. MUDr. Jan Plzák, Ph.D.

Klinika otorinolaryngologie a chirurgie hlavy a krku 1. LF UK a FN v Motole, Praha

- 1 Vrána, D.: Imunoterapie nádorů hlavy a krku. *Onkologie*, 2019, 13, s. 273–277.
- 2 Gurín, D. – Slávik, M. – Shatokhina, T., et al.: Current perspective on HPV-associated oropharyngeal carcinomas and the role of p16 as a surrogate marker of high-risk HPV. *Klinická onkologie*, 2019, 32, s. 252–260.
- 3 Tsao, S. W. – Tsang, C. M. – Lo, K. W.: Epstein-Barr virus infection and nasopharyngeal carcinoma. *Philos Trans R Soc Lond B Biol Sci*, 2017, 372.
- 4 Dunder, P. – Matěj, R. – Ryška, A.: Doporučení pro testování PD-L1: metodika testování a reportování výsledků. Společnost českých patoloů, 2021. Dostupné z: <https://www.patologie.info/soubory/all/P%201.pdf>, vyhledáno 14. 2. 2023.
- 5 Smilek, P. – Mechl, Z. – Brancíková, D., et al.: O nádorech hlavy a krku. Česká onkologická společnost, 2022. Dostupné z: <https://www.linkos.cz/pacient-a-rodina/onkologicke-diagnozy/nadory-hlavy-a-krku-c00-14-c30-32/o-nadorech-hlavy-a-krku/>, vyhledáno 14. 2. 2023.
- 6 Nádory hlavy a krku. Masarykův onkologický ústav Brno, 2022.

Dostupné z: <https://www.mou.cz/nadory-hlavy-a-krku/t1493>, vyhledáno 14. 2. 2023.

- 7 Mooren, J. J. – Gültekin, S. E. – Straetmans, J. M. J. A. A., et al.: P16 (INK4A) immunostaining is a strong indicator for high-risk HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk HPV-infection in head and neck papillomas and laryngeal dysplasias. *Int J Cancer*, 2014, 134, s. 2108–2117.
- 8 Horáková, Z. – Slávik, M. – Veselý, K., et al.: Prognosis of HPV-positive and -negative oropharyngeal cancers depends on the treatment modality. *Klinická onkologie*, 2019, 32, s. 187–196.
- 9 Mechl, Z. – Neuwirthová, J.: Cetuximab rozšiřuje léčebné možnosti

nádorů hlavy a krku. *Onkologie*, 2011, 5, s. 2019–2224.

- 10 Cramer, J. D. – Burtneiss, B. – Ferris, R. L.: Immunotherapy for head and neck cancer: Recent advances and future directions. *Oral Oncol*, 2019, 99, s. 104460.
- 11 Mechl, Z. – Bráncíková, D. – Pejčoch, R.: Jak dalece může HPV ovlivnit léčbu karcinomu orofaryngu? In: XIX. Jihočeské onkologické dny, 2012.
- 12 ASCO 2019: KEYNOTE 048 highlights role of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. Dostupné z: <https://www.practiceupdate.com/content/asco-2019-keynote-048-highlights-role-of-pembrolizumab-in-recurrent-metastatic-head-and-neck-squamous-cell-carcinoma/84642>,

vyhledáno 14. 2. 2023.

- 13 Keytruda, SPC.
- 14 Nekolná, M. – Drahokoupilová, E. – Starý, J.: Nasofaryngeální karcinom u dospívajících – zkušenosti s léčbou na Klinice dětské hematologie a onkologie FN Motol, Praha. In: XXXI. Brněnské onkologické dny, 2007. Dostupné z: <https://www.linkos.cz/lekar-a-multidisciplinari-tym/kongresy/po-kongresu/data-baze-tuzemskych-onkologickych-konferencnich-abstrakt/nasofaryngealni-karcinom-u-dospivajicich-zkusenosti-s-lecbou-na-klinice-det-ske-hv>, vyhledáno 14. 2. 2023.
- 15 Opdivo, SPC.

## Pětiletý update celkového přežití ve studiích s imuno-onkoterapií u nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Reck, M. – Rodriguez-Abreu, D. – Robinson, A. G., et al.: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score  $\geq 50\%$ . *J Clin Oncol*, 2021, 39, s. 2339–2349.
- 2 Garassino, M. C. – Gadgeel, S. M. – Speranza, G., et al.: 973MO – KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic non-squamous NSCLC. *Ann Oncol*, 2022, 33, suppl. 7, s. S448–S554.
- 3 Novello, S. – Kowalski, D. M. – Luft, A., et al.: 974MO – 5-year update from KEYNOTE-407: pembrolizumab plus chemotherapy in squamous

non-small-cell lung cancer (NSCLC). *Ann Oncol*, 2022, 33, suppl. 7, s. S448–S554.

- 4 Spigel, D. R. – Faires-Finn, C. – Gray, J. E., et al.: Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *J Clin Oncol*, 2022, 40, s. 1301–1311.
- 5 Wakelee, H. A. – Altorki, N. K. – Zhou, C., et al.: IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2021, 39, suppl. 15, s. 8500–8500.

- 6 Wakelee, H. – Altorki, N. – Felip, E., et al.: IMpower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. Dostupné z: <https://doi.org/10.1016/j.jtho.2022.07.013>, vyhledáno 22. 2. 2023.
- 7 Brahmer, J. R., et al.: LBA51 – KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS)  $\geq 50\%$ . *Ann Oncol*, 2020, 31, suppl. 4, s. S114–S1215.

## CAR-T lymfocyty v terapii ne Hodgkinových lymfomů

MUDr. Kamila Polgárová, Ph.D. | MUDr. Tereza Líkařová | prof. MUDr. Marek Trněný, CSc.

I. interní klinika – klinika hematologie VFV v Praze a 1. LF UK, Praha

- 1 Zhang, Y. – Zhang, Z.: The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol*, 2020, 17, s. 807–821.
- 2 Sadelain, M. – Brentjens, R. – Rivière, I.: The basic principles of chimeric antigen receptor design. *Cancer Discov*, 2013, 3, s. 388–398.
- 3 Duell, J. – Lurati, S. – Dittrich, M., et al.: First generation chimeric antigen receptor display functional defects in key signal pathways upon antigen stimulation. *Blood*, 2010, 116, s. 2088.
- 4 Foster, M. C., et al.: Utility of a safety switch to abrogate CD19 CAR T-cell-associated neurotoxicity. *Blood*, 2021, 137, s. 3306–3309.
- 5 O'Brien, S., et al.: A first-in-human phase 1, multicenter, open-label study of CB-010, a next-generation CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed/refractory B cell non-Hodgkin lymphoma (ANTLER Study). *Blood*, 2022, 140, s. 9457–9458.
- 6 Wang, Y., et al.: Sustained remission and decreased severity of CAR T-cell related adverse events: a pivotal study report of CNCT19 (inacabtagene autoleucel) treatment in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-Cell ALL) in Chin. *Blood*, 2022, 140, s. 1598–1600.
- 7 Kašťánková, I. – Štách, M. – Žížková, H., et al.: Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR cells. *Mol Ther Methods Clin Dev*, 2021, 23, s. 119–127.
- 8 Zhao, J. – Song, Y. – Liu, D.: Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. *J Hematol Oncol*, 2019, 12, s. 17.
- 9 Polgárová, K. – Otáhal, P. – Šálek, C., et al.: Chimeric antigen receptor based cellular therapy for treatment of T-cell malignancies. *Front Oncol*, 2022, 12, s. 876758.
- 10 Siegler, E. L. – Kenderian, S. S.: Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. *Front Immunol*, 2020, 11, doi: 10.3389/fimmu.2020.01973.
- 11 Park, J. H. – Sauter, C. S. – Palomba, M. L., et al.: A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma. *Blood*, 2021, 138, suppl. 1, s. 96.
- 12 Raj, S., et al.: Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy. *Blood*, 2022, 140, s. 648–650.
- 13 Rejeski, K., et al.: CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood*, 2021, 138, s. 2499–2513.
- 14 Gödel, P. – Sieg, N. – Heger, J.-M., et al.: Hematologic rescue of CAR T-cell-mediated prolonged pancytopenia using autologous peripheral blood hematopoietic stem cells in a lymphoma patient. *Hemaphys*, 2021, 5, s. e545.
- 15 Liu, W., et al.: Long-term activity of combining CNCT19 with HDT/ASCT in Refractory large B-cell lymphoma: two-year follow-up of a prospective phase 1/2 clinical trial. *Blood*, 2022, 140, s. 7472–7473.
- 16 Jaeger, U., et al.: Myc expression and tumor-infiltrating T cells are associated with response in patients (Pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) treated with tisagenlecleucel in the Juliet Trial. *Blood*, 2020, 136, s. 48–49.
- 17 Vercellino, L., et al.: Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv*, 2020, 4, s. 5607–5615.
- 18 Locke, F. L., et al.: Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in ZUMA-7. *Blood*, 2022, 140, s. 638–640.
- 19 Barba, P., et al.: YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma: Phase I study update. *Blood*, 2022, 140, s. 1056–1059.
- 20 Anguille, S., et al.: Initial clinical results of Atalanta-1, a phase I/II trial of point-of-care manufactured GLPG5102 (19CP02) in RR NHL. *Blood*, 2022, 140, s. 10323–10324.
- 21 Iacoboni, G., et al.: Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. *Blood*, 2022, 140, s. 1592–1594.
- 22 Tantaló, D. G. M., et al.: Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. *J Immunother Cancer*, 2021, 9, s. e002555.
- 23 Cheloni, G., et al.: Durable response to CD19 CAR T cell therapy is associated with cytotoxicity and clonal expansion of the native T cell repertoire. *Blood*, 2022, 140, s. 644–645.
- 24 Greenbaum, U., et al.: Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CAR-T). *Blood*, 2022, 140, s. 4636–4638.
- 25 Kamdar, M., et al.: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 transform study. *Blood*, 2021, 138, s. 91.
- 26 Locke, F. L., et al.: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol*, 2019, 20, s. 31–42.
- 27 Jaglowski, S., et al.: Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the Center for International Blood

& Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. *Blood*, 2019, 134, s. 766.

- 28 Jacobson, C., et al.: Long-term ( $\geq 4$  year and  $\geq 5$  year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL). *Blood*, 2021, 138, s. 1764.
- 29 Schuster, S. J., et al.: Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*, 2021, 22, s. 1403–1415.
- 30 Jacobson, C. A., et al.: Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. *J Clin Oncol*, 2020, 38, s. 3095–3106.
- 31 Yassine, F. – Iqbal, M. – Murthy, H., et al.: Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. *Curr Res Transl Med*, 2020, 68, s. 159–170.
- 32 Lin, R. J., et al.: Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. *Haematologica*, 2021, 106, s. 255–258.
- 33 Lunning, M. A., et al.: Outcomes of axicabtagene ciloleucel in comparison with chemoimmunotherapy (CIT) in an elderly population for treatment of relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after two or more lines of prior therapy. *Blood*, 2022, 140, s. 1852–1855.
- 34 Bachy, E., et al.: A propensity score-matched comparison of Axi-Cel and Tisa-Cel for relapsed/refractory diffuse large B-cell lymphoma in real-life: A Lysa Study from the Descar-T Registry. *Blood*, 2021, 138, s. 92.
- 35 Kwon, M., et al.: Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. *Haematologica*, 2022, 108, s. 110–121.
- 36 Jacobson, C. A., et al.: A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory primary and secondary central nervous system lymphoma (CNSL). *Blood*, 2022, 140, s. 1060–1061.
- 37 Locke, F. L., et al.: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 640–654.
- 38 Kamdar, M., et al.: Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet*, 2022, 399, s. 2294–2308.
- 39 Bishop, M. R., et al.: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. *N Engl J Med*, 2021, 386, s. 629–639.
- 40 Shadman, M., et al.: Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. *Blood*, 2021, 139, s. 1330–1339.
- 41 Houot, R., et al.: Axicabtagene ciloleucel as second-line therapy for

- large B-cell lymphoma in transplant-ineligible patients: primary analysis of Alysante, a phase 2 Lysa study. *Blood*, 2022, 140, s. 410–411.
- 42 **Neelapu, S. S., et al.**: Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med*, 2022, 28, s. 735–742.
  - 43 **Wang, M., et al.**: Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. *J Clin Oncol*, 2022, doi: 10.1200/JCO.21.02370.
  - 44 **Iacoboni, G., et al.**: Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. *Blood Adv*, 2022, 6, s. 3606–3610.
  - 45 **Batlevi, C. L., et al.**: Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. *Blood Cancer J*, 2020, 10, s. 74.
  - 46 **Sortais, C., et al.**: Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. *Ann Hematol*, 2020, 99, s. 1595–1604.
  - 47 **Fowler, N. H., et al.**: Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med*, 2022, 28, s. 325–332.
  - 48 **Jacobson, C. A., et al.**: Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol*, 2022, 23, s. 91–103.
  - 49 **Hao, Y., et al.**: Utilization of external control arm to contextualize clinical efficacy of tisagenlecleucel treated among patients with relapsed/refractory follicular lymphoma from the single-arm Elara trial. *Blood*, 2021, 138, s. 4506.
  - 50 **Ghione, P., et al.**: Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. *Blood*, 2022, 140, s. 851–860.
  - 51 **Todorovic, Z., et al.**: CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. *Curr Oncol*, 2022, 29, s. 3647–3657.
  - 52 **Flinn, I., et al.**: ZUMA-8: A phase 1/2 multicentre study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). *J Clin Oncol*, 2019, 37, TPS7566–TPS7566.
  - 53 **Mamonkin, M. – Rouce, R. H. – Tashiro, H., et al.**: A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. *Blood*, 2015, 126, s. 983–992.
  - 54 **Georgiadis, C., et al.**: Base-edited CAR T cells for combinational therapy against T-cell malignancies. *Leukemia*, 2021, 35, s. 3466–3481.
  - 55 **Pan, J., et al.**: Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. *J Clin Oncol*, 2021, 39, s. 3340–3351.
  - 56 **Alcantara, M. – Tesio, M. – June, C. H. – Houot, R.**: CART-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. *Leukemia*, 2018, 32, s. 2307–2315.
  - 57 **Maciocia, P. M., et al.**: Targeting the T cell receptor  $\beta$ -chain constant region for immunotherapy of T cell malignancies. *Nat Med*, 2017, 23, s. 1416–1423.
  - 58 **Zhang, L. – Meng, Y. – Feng, X., et al.**: CAR-NK cells for cancer immunotherapy: from bench to bedside. *Biomark Res*, 2022, 10, s. 12.
  - 59 **Subklewe, M.**: BiTEs better than CAR T cells. *Blood Adv*, 2021, 5, s. 607–612.
  - 60 **Wang, M., et al.**: KTE-X19 CART-cell therapy in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*, 2020, 382, s. 1331–1342.
  - 61 **Nastoupil, L. J., et al.**: Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CART consortium. *J Clin Oncol*, 2020, 38, s. 3119–3128.
  - 62 **Bachy, E., et al.**: A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nat Med*, 2022, 28, s. 2145–2154.
  - 63 **Godwin, J. E., et al.**: Outreach: results from a phase 2 Study of liso-cabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (Pts) with R/R large B-cell lymphoma (LBCL). *Blood*, 2021, 138, s. 1762.

## Polatuzumab vedotin v léčbě agresivních lymfomů

MUDr. Prokop Vodička | prof. MUDr. Marek Trněný, CSc. I. interní klinika – hematologie, 1. LF UK a VFN v Praze

- 1 **Olejniczak, S. H. – Stewart, C. C. – Donohue, K., et al.**: A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. *Immunol Invest*, 2006, 35, s. 93–114.
- 2 **Dornan, D. – Bennett, F. – Chen, Y., et al.**: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. *Blood*, 2009, 114, s. 2721–2729.
- 3 **Morschhauser, F. – Flinn, I. W. – Advani, R., et al.**: Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). *Lancet Haematol*, 2019, 6, s. e254–e265.
- 4 **Phillips, T. – Brunvand, M. – Chen, A. I., et al.**: Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase Ib/II study. *Am J Hematol*, 2022, 97, s. E24–E27.
- 5 **Topp, M. S. – Eradat, H. – Florschütz, A., et al.**: Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma. *J Cancer Res Clin Oncol*, 2023, 149, s. 811–817.
- 6 **Sehn, L. H. – Herrera, A. F. – Flowers, C. R., et al.**: Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. *J Clin Oncol*, 2020, 38, s. 155–165.
- 7 **Sehn, L. H. – Hertzberg, M. – Opat, S., et al.**: Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. *Blood*, 2020, 136, suppl. 1, s. 17–19.
- 8 **Liebers, N. – Duell, J. – Fitzgerald, D., et al.**: Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. *Blood Adv*, 2021, 5, s. 2707–2716.
- 9 **Vodička, P. – Benesova, P. – Janikova, A., et al.**: Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world. *Eur J Haematol*, 2022, 109, s. 162–165.
- 10 **Herrera, A. F. – Chen, L. – Crombie, J. L., et al.**: Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma. *Blood*, 2022, 140, suppl. 1, s. 1065–1067.
- 11 **Tilly, H. – Morschhauser, F. – Sehn, L. H., et al.**: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med*, 2022, 386, s. 351–363.
- 12 **Hutchings, M. – Sureda, A. – Terol, M. J., et al.**: Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). *Blood*, 2021, 138, s. 525.
- 13 **Minson, A. – Hamad, N. – Yannakou, C. K., et al.**: Trial in progress: a multicentre, parallel arm, open-label trial of frontline R-CHOP/polatuzumab vedotin-RCHP and glofitamab in younger patients with higher risk diffuse large B cell lymphoma (COALITION). *Blood*, 2021, 138, s. 3571.
- 14 **Budde, L. E. – Ghosh, N. – Chavez, J. C., et al.**: Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL). *J Clin Oncol*, 2021, 39, suppl. 15, s. 7520–7520.
- 15 **Olszewski, A. J. – Budde, L. E. – Chavez, J., et al.**: Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and  $\geq$ 65 years with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and  $\geq$  1 prior therapy: subgroup analysis of a phase Ib/II study. *Blood*, 2022, 140, suppl. 1, s. 3757–3759.
- 16 **Westin, J. – Olszewski, A. J. – Fogliatto, L. M., et al.**: SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin versus rituximab in combination with gemcitabine plus oxaliplatin in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. *Blood*, 2022, 140, suppl. 1, s. 3771–3772.
- 17 **Gouni, S. – Rosenthal, A. C. – Crombie, J. L., et al.**: A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. *Blood Adv*, 2022, 6, s. 2757–2762.
- 18 **Diefenbach, C. – Abrisqueta, P. – Gonzalez-Barca, E., et al.**: Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. *J Clin Oncol*, 2021, suppl. 15, s. 7512–7512.
- 19 **Diefenbach, C. – Kahl, B. S. – McMillan, A., et al.**: Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. *Lancet Haematol*, 2021, 8, s. e891–e901.
- 20 **Lasater, E. A. – Amin, D. N. – Bannerji, R., et al.**: Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study. *Am J Hematol*, 2023, 98, s. 449–463.

## Můžeme myelom zcela vyléčit? Daratumumab, elotuzumab a isatuximab v léčbě mnohočetného myelomu

MUDr. František Sedláč I. interní klinika – klinika hematologie, 1. LF UK a VFN v Praze

- 1 **Sung, H., et al.**: Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*, 2021, 71, s. 209–249.
- 2 **Boyle, P. – Ferlay, J.**: Cancer incidence and mortality in Europe, 2004. *Ann Oncol*, 2005, 16, s. 481–488.
- 3 **Sigrun, T., et al.**: Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. *Haematologica*, 2018, 103, s. e412–e415.
- 4 **Bagchi, S.**: Siltuximab in transplant-ineligible patients with myeloma. *Lancet Oncol*, 2014, 15, s. e309.
- 5 **Romano, A., et al.**: Mechanisms of action of the new antibodies in Use in multiple myeloma. *Front Oncol*, 2021, 11, doi.org/10.3389/fonc.2021.684561.
- 6 **Lonial, S., et al.**: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet*, 2016, 387, s. 1551–1560.
- 7 **Bahlis, N. J., et al.**: Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia*, 2020, 34, s. 1875–1884.
- 8 **Dimopoulos, M. A., et al.**: Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. *J Clin Oncol*, 2023, 41, s. 1590–1599.
- 9 **Mateos, M. V., et al.**: Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. *Clin Lymphoma Myeloma Leuk*, 2020, 20, s. 509–518.
- 10 **Sonneveld, P., et al.**: Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. *J Clin Oncol*, 2023, 41, s. 1600–1609.
- 11 **Moreau, P., et al.**: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*, 2019, 394, s. 29–38.
- 12 **Moreau, P., et al.**: Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 1378–1390.
- 13 **Voorhees, P. M., et al.**: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. *Blood*, 2020, 136, s. 936–945.
- 14 **Mateos, M. V., et al.**: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet*, 2020, 395, s. 132–141.
- 15 **Facon, T., et al.**: Daratumumab, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 1582–1596.
- 16 **Mateos, M. V., et al.**: Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol*, 2020, 7, s. e370–e380.
- 17 **Chari, A., et al.**: Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. *Br J Haematol*, 2021, 192, s. 869–878.
- 18 **Usmani, S. Z., et al.**: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. *Lancet Oncol*, 2023, 24, s. 1000–1010.

- 2022, 23, s. 65–76.
- 19 **Dimopoulos, M. A., et al.:** Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 801–812.
  - 20 **Dimopoulos, M., et al.:** Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood*, 2021, 137, s. 1154–1165.
  - 21 **Attal, M., et al.:** Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*, 2019, 394, s. 2096–2107.
  - 22 **Richardson, P. G., et al.:** Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. *Lancet Oncol*, 2022, 23, s. 416–427.
  - 23 **Moreau, P., et al.:** Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. *Lancet*, 2021, 397, s. 2361–2371.
  - 24 **Moreau, P., et al.:** VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM). *Ann Oncol*, 2022, 33, s. 664–665.
  - 25 **Leypoldt, L. B., et al.:** Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRD) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. *Leukemia*, 2022, 36, s. 885–888.
  - 26 **Ocio, E. M., et al.:** Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. *Blood*, 2018, 132, suppl. 1, s. 595–595.
  - 27 **Ghobrial, I., et al.:** P-137: ITHACA, a randomized multicenter phase 3 study of isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma: safety run-in preliminary results. *Clinical Lymphoma Myeloma and Leukemia*, 2021, 21, s. S109–S110.
  - 28 **Magen, H. – Muchtar, E.:** ELOTUZUMAB: the first approved monoclonal antibody for multiple myeloma treatment. *Ther Adv Hematol*, 2016, 7, s. 187–195.
  - 29 **Zonder, J. A., et al.:** A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. *Blood*, 2012, 120, s. 552–559.
  - 30 **Jakubowski, A., et al.:** Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. *Blood*, 2016, 127, s. 2833–2840.
  - 31 **Dimopoulos, M. A., et al.:** ELOTUZUMAB plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. *Cancer*, 2018, 124, s. 4032–4043.
  - 32 **Dimopoulos, M. A., et al.:** ELOTUZUMAB plus pomalidomide and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer J*, 2020, 10, s. 91.
  - 33 **Dimopoulos, M. A., et al.:** ELOTUZUMAB plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. *J Clin Oncol*, 2022, 41, s. 568–578.

## Přehled aktuálních doporučení a hlavních směrů v terapii chronické lymfocytární leukemie

MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie, Všeobecná fakultní nemocnice a 1. LF UK, Praha

- 1 **Hallek, M., et al.:** iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.
- 2 **Hallek, M. – Fischer, K. – Fingerle-Rowson, G., et al.:** Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*, 2010, 376, s. 1164–1174.
- 3 **Sharman, J. P. – Egedy, M. – Jurczak, W., et al.:** Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. *Leukemia*, 2022, 36, s. 1171–1175.
- 4 **Jurczak, W. – Pluta, A. – Wach, M., et al.:** Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up. *J Clin Oncol*, 2022, 40, suppl. 16, s. 7538.
- 5 **Byrd, J. C. – Hillmen, P. – Ghia, P., et al.:** Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. *J Clin Oncol*, 2021, 39, s. 3441–3452.
- 6 **Munir, T., et al.:** Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am J Hematol*, 2019, 94, s. 1353–1363.
- 7 **Furman, R. R., et al.:** Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007.
- 8 **Seymour, J. F., et al.:** Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 9 **Seymour, J. F. – Kipps, T. J. – Eichhorst, B. F., et al.:** Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood*, 2022, 140, s. 839–850.
- 10 **Al-Sawaf, O., et al.:** Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2020, 21, s. 1188–1200.
- 11 **Tam, C. S., et al.:** Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *Lancet Oncol*, 2022, 23, s. 1031–1043.
- 12 **Kater, A. P. – Owen, C. – Moreno, C., et al.:** Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. *NEJM Evid*, 2022, 1, EVID02200006.
- 13 **Wierda, W. G. – Allan, J. N. – Siddiqi, T., et al.:** Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. *J Clin Oncol*, 2021, 39, s. 3853–3865.
- 14 **Gauthier, J. – Hirayama, A. V. – Purusho, J., et al.:** Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. *Blood*, 2020, 135, s. 1650–1660.

## Terapeutické možnosti blokady komplementu v léčbě atypického hemolyticko-uremického syndromu

prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a VFN v Praze

- 1 **Fakhouri, F. – Zuber, J. – Frémeaux-Bacchi, V., et al.:** Haemolytic uraemic syndrome. *Lancet*, 2017, 390, s. 681–696.
- 2 **Goodship, T. H. J. – Cook, T. H. – Fakhouri, F., et al.:** Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*, 2017, 91, s. 539–551.
- 3 **Loirat, C. – Fakhouri, F. – Ariceta, G., et al.:** An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol*, 2016, 31, s. 15–39.
- 4 **Caprioli, J. – Noris, M. – Briosis, S., et al.:** Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood*, 2006, 108, s. 1267–1279.
- 5 **Frémeaux-Bacchi, V. – Fakhouri, F. – Garnier, A., et al.:** Genetics and outcome of atypical hemolytic uremic syndrome: a nation wide French series comparing children and adults. *Clin J Am Soc Nephrol*, 2013, 8, s. 554–562.
- 6 **Keating, G. M.:** Eculizumab: a review of its use in atypical haemolytic-uraemic syndrome. *Drugs*, 2013, 73, s. 2053–2066.
- 7 **Legendre, C. M. – Licht, C. – Muus, P., et al.:** Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med*, 2013, 368, s. 2169–2181.
- 8 **Loirat, C. – Frémeaux-Bacchi, V.:** Hemolytic uremic syndrome recurrence after renal transplantation. *Pediatr Transplant*, 2008, 12, s. 619–629.
- 9 **Licht, C. – Greenbaum, L. A. – Muus, P., et al.:** Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int*, 2015, 87, s. 1061–1073.
- 10 **Wijnsma, K. L. – Duineveld, C. – Wetzels, J. F. M., et al.:** Eculizumab in hemolytic uremic syndrome: strategies to ward restrictive use. *Pediatr Nephrol*, 2019, 34, s. 2261–2277.
- 11 **Walle, J. V. – Delmas, Y. – Ardissino, G., et al.:** Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. *J Nephrol*, 2017, 30, s. 127–134.
- 12 **Ardissino, G. – Testa, S. – Possenti, I., et al.:** Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. *Am J Kidney Dis*, 2014, 64, s. 633–637.
- 13 **Fakhouri, F. – Fila, M. – Provot, F., et al.:** Pathogenic variants in complement genes and risk of atypical hemolytic syndrome relapse after eculizumab discontinuation. *Clin J Am Soc Nephrol*, 2017, 12, s. 50–59.
- 14 **Macia, M. – de Alvaro Moreno, F. – Dutt, T., et al.:** Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic-uraemic syndrome. *Clin Kidney J*, 2017, 10, s. 310–319.
- 15 **Fakhouri, F. – Fila, M. – Hummel, A., et al.:** Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. *Blood*, 2021, 137, s. 2438–2449.
- 16 **Bouwmeester, R. N. – Duineveld, C. – Kioa, L., et al.:** Early eculizumab with drawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREIHUS study. *Kidney Int Rep*, 2023, 8, s. 91–102.
- 17 **Noris, M. – Remuzzi, G.:** Every fifteen days forever? *Kidney Int Rep*, 2023, 8, s. 4–7.
- 18 **Olson, R. – Lu, E. – Sulpizio, E., et al.:** When to stop eculizumab in complement-mediated thrombotic microangiopathies. *Am J Nephrol*, 2018, 48, s. 96–107.
- 19 **Acosta-Medina, A. A. – Moyer, A. M. – Go, R. S., et al.:** Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation. *Blood Adv*, 2023, 7, s. 340–350.
- 20 **Rondeau, E. – Scully, M. – Ariceta, G., et al.:** The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. *Kidney Int Rep*, 2020, 97, s. 1287–1296.
- 21 **Fakhouri, F. – Hourmant, M. – Campistol, J. M., et al.:** Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. *Am J Kidney Dis*, 2016, 68, s. 84–93.
- 22 **Barbour, T. – Scully, M. – Ariceta, G., et al.:** Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. *Kidney Int Rep*, 2021, 6, s. 1603–1613.
- 23 **Ariceta, G. – Dixon, B. P. – Kim, H., et al.:** The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. *Kidney Int Rep*, 2021, 100, s. 225–237.
- 24 **Syed, Y. Y.:** Ravulizumab: A review in atypical haemolytic uraemic syndrome. *Drugs*, 2021, 81, s. 587–594.
- 25 **Tomazos, I. – Hatswell, A. J. – Cataland, S., et al.:** Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data. *Clin Nephrol*, 2022, 97, s. 261–272.
- 26 **Postma, A. J. – Quist, S. – de Jong, L.:** Cost-minimisation analysis of ravulizumab compared with eculizumab in patients with atypical hemolytic uremic syndrome (AHUS) in the Netherlands. 2022; poster EE52. Dostupné z: [https://www.ispor.org/docs/default-source/euro2022/ispor22postma-pdf.pdf?sfvrsn=2b1e0718\\_0\\_vyhledano](https://www.ispor.org/docs/default-source/euro2022/ispor22postma-pdf.pdf?sfvrsn=2b1e0718_0_vyhledano) 14. 3. 2023.
- 27 **Levy, A. R. – Chen, P. – Johnston, K., et al.:** Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. *J Med Econ*, 2022, 25, s. 249–259.
- 28 **Mauch, T. – Chladek, M. – Cataland, S., et al.:** Preference for ravulizumab over eculizumab: A real-world patient preference and life impact study on the treatment of atypical hemolytic uremic syndrome (abstrakt). Dostupné z: <https://abstracts.isth.org/abstract/preference-for-ravulizumab-over-eculizumab-a-real-world-patient-preference-and-life-impact-study-on-the-treatment-of-atypical-hemolytic-uremic-syndrome/>, vyhledáno 13. 3. 2023.
- 29 **Cammett, T. – Garlo, K. – Millman, E. E., et al.:** Exploratory prognostic biomarkers of complement-mediated thrombotic microangiopathy (CM-TMA) in adults with atypical hemolytic uremic syndrome (aHUS): Analysis of a phase III study of ravulizumab. *Mol Diagn Ther*, 2023, 27, s. 61–74.

# Biologická léčba u nemocných s AL amyloidózou

prof. MUDr. Romana Ryšavá, CSc. Klinika nefrologie, 1. LF UK a Všeobecná fakultní nemocnice v Praze

MUDr. Tomáš Pika, Ph.D. Hemato-onkologická klinika, LF UP a FN Olomouc

- Kyle, R. A. – Linos, A. – Beard, C. M., et al.: Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minnesota, 1950 through 1989. *Blood*, 1992, 79, s. 1817–1822.
- Merlini, G.: AL amyloidosis: diagnosis and prognosis. *Haematologica*, 2007, 92, suppl. 2, s. 58–59.
- Kyle, R. A.: Multiple myeloma and other plasma cell disorders. In: Hoffman, R. – Bentz, E. J. Jr. – Shattil, S. J., et al.: *Hematology: basic principles and practice*. New York, Churchill Livingstone, 1995, s. 1354–1374.
- Bird, J.: Guidelines on the diagnosis and management of AL amyloidosis. *Br J Haematol*, 2004, 125, s. 681–700.
- Rajkumar, S. V. – Gertz, M. A.: Advances in the treatment of amyloidosis. *New Engl J Med*, 2007, 356, s. 2413–2415.
- Palladini, G. – Dispenzieri, A. – Gertz, M. A., et al.: New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol*, 2012, 30, s. 4514–4549.
- Wechalekar, D. – Cibeleira, M. T. – Gibbs, S. D., et al.: Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. *Amyloid*, 2022, s. 1–15, doi: 10.1080/13506129.2022.2093635.
- Gavriatopoulou, M. – Musto, P. – Caers, J., et al.: European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, 2018, 32, s. 1883–1898.
- Pika, T. – Hájek, R., et al.: Diagnostika a léčba systémové AL amyloidózy. *Transfúze a hematologie dnes*, 2019, 19, suppl. 1, s. 6–40.
- Kastritis, E. – Palladini, G. – Minnema, M. C., et al.: Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. *N Engl J Med*, 2021, 385, s. 46–58.
- Palladini, G. – Kastritis, E. – Maurer, M. S., et al.: Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of Andromeda. *Blood*, 2020, 136, s. 71–80.
- Santhorawala, V. – Sarosiek, S. – Schulman, A., et al.: Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. *Blood*, 2020, 135, s. 1541–1547.
- Roussel, M. – Merlini, G. – Chevret, S., et al.: A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. *Blood*, 2020, 135, s. 1531–1540.
- Kaufman, G. P. – Schrier, S. L. – Lafayette, L. A., et al.: Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. *Blood*, 2017, 130, s. 900–902.
- Kimmich, C. R. – Terzer, T. – Benner, A., et al.: Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. *Blood*, 2020, 135, s. 1517–1530.
- Bianchi, G. – Zhang, Y. – Comenzo, R. L.: AL amyloidosis: current chemotherapy and immune therapy treatment strategies. *Am Coll Cardiol Cardio Onc*, 2021, 3, s. 467–487.
- Sidiqi, M. H. – Al Saleh, A. S. – Leung, N., et al.: Venetoclax for the treatment of translocation (11;14) AL amyloidosis. *Blood Cancer J*, 2020, 10, s. 55.
- Premkumar, V. J. – Lentzsch, S. – Pan, S., et al.: Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. *Blood Cancer J*, 2021, 11, s. 10.
- Gertz, M. A. – Landau, H. – Comenzo, R. L., et al.: First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. *J Clin Oncol*, 2016, 34, s. 1097–1103.
- Gertz, M. A. – Cohen, A. D. – Comenzo, R. L., et al.: Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients. *Blood*, 2019, 134, s. 3166.
- Edwards, C. V. – Rao, N. – Bhutani, D., et al.: Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. *Blood*, 2021, 138, s. 2632–2641.
- Khouri, J. – Anwer, F. – Samaras, C. J., et al.: Safety, tolerability and efficacy of Cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of Cael-101 in patients with AL amyloidosis. *Blood*, 2020, 136, s. 21.
- Bodin, K. – Elmerich, S. – Kahan, M. C., et al.: Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. *Nature*, 2010, 468, s. 93–97.
- Richards, D. B. – Cookson, L. M. – Berges, A. C., et al.: Therapeutic clearance of amyloid by antibodies to serum amyloid P component. *N Engl J Med*, 2015, 373, s. 1106–1114.
- Kumar, S. – Dispenzieri, A. – Lacy, M. Q., et al.: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol*, 2012, 30, s. 989–995.
- Wechalekar, A. D. – Schonland, S. O. – Kastritis, E., et al.: A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood*, 2013, 121, s. 3420–3427.
- Merlini, G. – Seldin, D. C. – Gertz, M. A.: Amyloidosis: pathogenesis and new therapeutic options. *J Clin Oncol*, 2011, 29, s. 1924–1933.

## Update systémové léčby atopického ekzému podle EuroGuiDerm – reportáž

- AbbVie Press Release. CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis. 25. 6. 2021. Dostupné z: <https://news.abbvie.com/news/press-releases/chmp-recommends-approval-rinvoq-upadacitinib-for-treatment-atopic-dermatitis.htm>, vyhledáno 14. 3. 2023.
- Lilly News Release. CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis. 18. 9. 2020. Dostupné z: <https://investor.lilly.com/news-releases/news-release-details/chmp-recommends-approval-lillys-baricitinib-treatment-adults-0>, vyhledáno 14. 3. 2023.
- Pfizer Press Release. European Commission Approves Pfizer's Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis. 10. 12. 2021. Dostupné z: [https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqo-abrocitinib#:~:text=\(NYSE%3A%20PFE\)%20today%20announced,are%20candidates%20for%20systemic%20therapy](https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqo-abrocitinib#:~:text=(NYSE%3A%20PFE)%20today%20announced,are%20candidates%20for%20systemic%20therapy), vyhledáno 14. 3. 2023.
- Pfizer Press Release. Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis. 15. 10. 2021. Dostupné z: <https://www.pfizer.com/news/press-release/press-release-detail/pfizers-abrocitinib-receives-positive-chmp-opinion>, vyhledáno 14. 3. 2023.
- Via Ritzau. LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis. 23. 4. 2021. Dostupné z: <https://via.ritzau.dk/pressemeddelelse/leo-pharma-receives-positive-chmp-opinion-of-adtralza-tralokinumab-for-the-treatment-of-adults-with-moderate-to-severe-atopic-dermatitis?publisherId=12353927&releaseId=13620649>, vyhledáno 14. 3. 2023.
- Wollenberg, A., et al.: European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. *J Eur Acad Dermatol Venereol*, 2022, 36, s. 1409–1431.
- Wollenberg, A., et al.: European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. *J Eur Acad Dermatol Venereol*, 2022, 36, s. 1904–1926.
- Wollenberg, A., et al.: EuroGuiDerm Guideline on Atopic Eczema. Version 2.1. Prosinec 2022. Dostupné z: <https://guidelines.edf.one/guidelines/atopic-eczema>, vyhledáno 14. 3. 2023.

## Perioperační úpravy antirevmatické léčby

MUDr. Liliana Šedová | MUDr. Jana Tomasová-Studýnková, Ph.D. Revmatologický ústav, Praha

- Šedová L. – Tomasová-Studýnková J.: Doporučení České revmatologické společnosti 2020 k perioperační úpravě léčby zánětlivých revmatických onemocnění. *Čes Revmatol*, 2020, 28, s. 5–15.
- Goodman, S. M. – Springer, B. D. – Chen, A. F., et al.: 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. *Arthritis Care Res*, 2022, 74, s. 1399–1408.
- Goodman, S. M. – Springer, B. D. – Chen, A. F., et al.: 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. *Arthritis Rheumatol*, 2022, 74, s. 1464–1473.

## Terapie komplikované psoriatické artritidy inhibítorem IL-17 – kazuistika

MUDr. Jan Tomš, Ph.D. II. interní gastroenterologická klinika LF UK a FN Hradec Králové

- Gupta, S. – Zyrimi, Z. – Hughes, D. M., et al.: Comorbidities in psoriatic arthritis: a systematic review and meta analysis. *Rheumatol Int*, 2021, 41, s. 275–284.
- Štofa, J.: Biologická léčba psoriatické artritidy. *Vnitřní Léč*, 2018, 64, s. 127–135.
- McInnes, I. B. – Sawyer, L. M. – Markus, K., et al.: Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. *RMD Open*, 2022, 8, s. e002074.
- Gossec, L. – Baraliakos, X. – Kerschbaumer, A., et al.: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 700–712.
- Kavanaugh, A. – McInnes, I. B. – Mease, P. J., et al.: Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. *J Rheumatol*, 2016, 43, s. 1713–1717.
- Siegel, S. A. R. – Winthrop, K. L.: In the real world: infections associated with biologic and small molecule therapies in psoriatic arthritis and psoriasis. *Curr Rheumatol Rep*, 2019, 21, s. 36.
- Li, X. – Andersen, K. L. – Chang, H. Y., et al.: Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. *Ann Rheum Dis*, 2020, 79, s. 285–291.
- McInnes, I. B. – Behrens, F. – Mease, P. J., et al.: Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. *Lancet*, 2020, 395, s. 1496–1505.
- Vasoo, S. – Gurnani, P. – Agustín, T., et al.: Chest pain as presenting symptom of Staphylococcus aureus epidural abscess associated with anti-tumor necrosis factor and methotrexate therapy. *J Clin Rheumatol*, 2009, 15, s. 396–398.
- Rose, A. M. – Barnett, J. – Morris-Jones, S., et al.: Staphylococcus lugdunensis septic arthritis and epidural abscess in a patient with rheumatoid arthritis receiving anti-tumour necrosis factor therapy. *Br J Rheum*, 2014, 53, DOI:10.1093/rheumatology/keu365.
- Antonelli, M. – Magrey, M.: Spinal epidural abscess on rituximab. *J Clin Rheum*, 2011, 17, s. 348.
- Vakil, M. – Crum-Cianflone, M. F.: Spinal epidural abscess: a series of 101 cases. *Am J Med*, 2017, 130, s. 1458–1463.

# Switch pacientna s Crohnovou nemocí z i. v. infliximabu na s. c. z důvodu pozitivitu protilátek proti infliximabu – kazuistika

MUDr. Iva Lerchová Centrum biologické terapie, Městská nemocnice Ostrava

- 1 Michnová, K.: Subkutánní infliximab – začátek éry biobetters v léčbě imunitně podmíněných zánětlivých onemocnění. *Gastroent Hepatol*, 2022, 76, s. 268–271.
- 2 Lukáš, M.: Remsima SC 120 mg – nová generace biosimilárních léčiv. *Gastroent Hepatol*, 2022, 76, s. 57–59.
- 3 Dalal, S. R. – Cohen, R. D.: What to do when biologic agents are not working in inflammatory bowel disease patients. *Gastroenterol Hepatol*, 2015, 11, s. 657–665.
- 4 Cheifetz, A. S. – Abreu, M. T. – Afif, W., et al.: A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. *Am J Gastroenterol*, 2021, 116, s. 2014–2025.
- 5 Horáková, M. – Vohánka, S.: Úskalí dávkování azathioprinu a cyklosporinu v terapii myastenii. *Neurol praxi*, 2017, 18, s. 309–313.
- 6 Deswal, S. – Srivastava, A.: Role of allopurinol in optimizing thiopurine therapy in patients with autoimmune hepatitis: A review. *J Clin Exp Hepatol*, 2017, 7, s. 55–52.
- 7 Kiszka-Kanowitz, M. – Theede, K., et al.: Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. *eClinicalMedicine* 2022, dostupné z: <https://doi.org/10.1016/j.eclinm.2022.101332>, vyhledáno 10. 3. 2023.
- 8 Pospíšilová, K. – Bronský, J.: Azathioprin v terapii idiopatických střevních zánětů u dětí – díl I: indikace, dávkování a nežádoucí účinky léčby thiopuriny. *Gastroent Hepatol*, 2021, 75, s. 500–507.

## Subkutánně aplikovaný infliximab, řešení při špatném žilním přístupu – kazuistika

MUDr. Vladimír Kojecký, Ph.D. Interní oddělení, Krajská nemocnice T. Bati, Zlín

- 1 Stoner, K. L. – Harder, H. – Followfield, L. J., et al.: Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. *Patient*, 2014, 8, doi: 10.1007/s40271-014-0075-y.
- 2 Khana, R. – Bressler, B. – Levesque, B. G., et al.: Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. *Lancet*, 2015, 386, s. 1825–1834.
- 3 Ben-Horin, S. – Chowers, Y.: Review article: loss of response to anti-TNF treatments in Crohn's disease. *Aliment Pharmacol Ther*, 2011, 33, s. 987–995.
- 4 Van Assche, G. – Vermeire, S. – Ballet, V., et al.: Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. *Gut*, 2012, 61, s. 229–234.
- 5 Alric, H. – Amiot, A. – Kirchgessner, J., et al.: The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. *Aliment Pharmacol Ther*, 2020, 51, s. 948–957.
- 6 Schreiber, S. – Ben-Horin, S. – Leszczyszyn, J., et al.: Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. *Gastroenterology*, 2021, 160, s. 2340–2353.
- 7 Smith, P. J. – Critchley, L. – Storey, D., et al.: Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study. *J Crohns Colitis*, 2022, 16, s. 1436–1446.

## Postavení upadacitinibu v léčbě idiopatických střevních zánětů

prof. MUDr. Milan Lukáš, CSc., AGAF Klinické a výzkumné centrum pro idiopatické střevní záněty, Klinické centrum ISCARE, a. s., a 1. LF UK, Praha

- 1 Lukáš, M. – Dušek, L.: Epidemiologie idiopatických střevních zánětů. In: Milan Lukáš (ed.): *Idiopatické střevní záněty. Současné trendy a mezioborová spolupráce*. Praha, Grada, 2021.
- 2 Lukáš, M.: Biologická a inovativní terapie. In: Milan Lukáš (ed.): *Pokroky v diagnostice a léčbě idiopatických střevních zánětů*. Praha, Galén, 2019.
- 3 Vermeire, S. – Zhou, W., et al.: Upadacitinib as an induction and maintenance therapy for moderately to severe ulcerative colitis: results from three phase 3, multicenter, double blind, randomized trials. *Lancet*, 2022, 399, s. 2113–2128.
- 4 Colombel, J. F. – Cao, Q. – Ghosh, S., et al.: Effect of upadacitinib treatment on extraintestinal manifestations in patients with moderate to severe ulcerative colitis: Results from the UPA Phase 3 programme. *Gastroenterology*, 2022, 162, suppl. S-968.
- 5 Peyrin-Biroulet, L. – Parkes, G. – Rodriguez, C., et al.: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologics. *JCC*, 2023, 17, suppl. 1, s. i20–i22.
- 6 Colombel, J. F. – Hisamatsu, T. – Bresso, F., et al.: Upadacitinib therapy reduces Crohn's disease symptoms within the first week of induction therapy. *JCC*, 2023, 17, suppl. 1, s. i102–i103.

## Jak zlepšit dostupnost a výsledky léčby revmatoidní artritidy biologickými léky

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Smolen, J. S. – Aletaha, D. – McInnes, I. B.: Rheumatoid arthritis. *Lancet*, 2016, 388, s. 2023–2038.
- 2 Smolen, J. S. – Aletaha, D. – Bijlsma, J. W. J., et al.: Treating rheumatoid arthritis to target: recommendations of an international Task Force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- 3 Gremese, E. – Salaffi, F. – Bosello, S. L., et al.: Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. *Ann Rheum Dis*, 2013, 72, s. 858–862.
- 4 Combe, B. – Kivitz, A. J. – Tanaka, Y., et al.: LB0001 Efficacy and safety of filgotinib for patients with rheumatoid arthritis with an adequate response to methotrexate: Finch 1 primary outcome results. *Ann Rheum Dis*, 2019, 78, s. 77–78.
- 5 Inotai, A. – Tomek, D. – Niewada, M., et al.: Identifying patient access barriers for tumor necrosis factor alpha inhibitor treatments in rheumatoid arthritis in five central eastern european countries. *Frontiers Rheum Front Pharmacol*, 2020, 11, s. 845, doi: 10.3389/fphar.2020.00845.
- 6 Smolen, J. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 7 Chatzidionysiou, K. – Lie, E. – Nasonov, E., et al.: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. *Ann Rheum Dis*, 2011, 70, s. 1575–1580.
- 8 Gabay, C. – Riek, M. – Lund Hetland, M., et al.: Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis*, 2016, 75, s. 1336–1342.
- 9 Závada, J., et al.: Stanovisko České revmatologické společnosti k personálnímu a technickému vybavení center biologické léčby v revmatologii a ke způsobu organizace jejich sítě. *Čes Revmatol*, 2019, 27, s. 6–8.
- 10 Fraenkel, L. – Bathon, J. – England, B. R., et al.: 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Care Res*, 2021, 73, s. 924–939.
- 11 Závada, J. – Uher, M. – Sisol, K. – Forejtová, Š. – Jarošová, K. – Mann, H. – Vencovský, J. – Pavelka, K.: A tailored approach to reduce dose of anti-TNF drugs maybe equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. *Ann Rheum Dis*, 2016, 75, s. 96–102.
- 12 Smolen, J. – Caporali, R. – Doerner, T., et al.: Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. *RMD Open*, 2021, 7, s. e001637.
- 13 Agboton, C. H. – Salameh, J.: Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe. *Expert Opin Biol Ther*, 2022, 22, s. 157–167.
- 14 Pavelka, K.: Biosimilární léky v revmatologii v roce 2018. *Acta Medica*, 2018, 9, s. 8–14.
- 15 Jørgensen, K. K. – Olsen, I. C., et al.: NOR-SWITCH study group: Switching from originator infliximab to biosimilar CT P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. *Lancet*, 2017, 389, s. 2304–2316.

## Postup v léčbě pacientů s revmatoidní artritidou a nedostatečnou odpovědí na první anti-TNF léčbu

doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 Taylor, P., et al.: Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. *Ther Adv Musculoskelet Dis*, 2022, 14, s. 1–14.



# Únava – závažný a nedoceněný projev revmatických onemocnění

doc. MUDr. Petr Bradna, CSc. II. interní gastroenterologická klinika, subkatedra revmatologie LF a FN Hradec Králové

- Almeida, C. – Choy, E. H. S. – Hewlett, S., et al.: Biologic interventions for fatigue in rheumatoid arthritis. *Cochrane Database Syst Rev*, 2016, s. CD008334.
- Shim, J. – Dean, L. E. – Karabayas, M., et al.: Quantifying and predicting the effect of anti-TNF therapy on axSpA-related fatigue: results from the BSRBR-AS registry and meta-analysis. *Rheumatology*, 2020, 59, s. 3408–3414.
- Cramp, F. – Hewlett, S. – Almeida, C., et al.: Non pharmacological interventions for fatigue in rheumatoid arthritis. *Cochrane Database Syst Rev*, 2013, s. CD008322
- Minnock, P. – Veale, D. J. – Bresnihan, B., et al.: Factors that influence fatigue status in patients with severe rheumatoid arthritis and good disease outcome following 6 month of TNF inhibitors therapy: a comparative analysis. *Clin Rheumatol*, 2015, 34, s. 1857–1865.
- Morris, G. – Berg, M. – Galicki, P., et al.: The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. *Mol Neurobiol*, 2015, 53, s. 1195–1219.
- Pope, J. E.: Management of fatigue in rheumatoid arthritis. *RMD Open*, 2020, 6, s. e001084.
- Provan, S. A. – Michelsen, B. – Sexton, J., et al.: Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. *RMD Open*, 2020, 6, s. e001372.
- Revicki, D. A. – Luo, M. P. – Wordsworth, P., et al.: Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). *J Rheumatol*, 2008, 35, s. 1346–1353.
- Schulman, E. – Bartlett, S. J. – Schieir, O., et al.: Overweight, obesity and the like likelihood of achieving sustained remission in early rheumatoid arthritis: results from a multicenter prospective cohort study. *Arthritis Care Res*, 2018, 70, s. 1185–1191.
- Strand, V. – Wright, G. C. – Bergmann, M. J., et al.: Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. *J Rheumatol*, 2015, 42, s. 2046–2054.
- Strand, V. – de Vlam, K. – Covarrubias Cobos, J. A., et al.: Tofacitinib or adalimumab versus placebo patients reported outcomes from OPAL broaden – a phase III study of active psoriatic arthritis inpatients with an inadequate response to conventional synthetic disease modifying antirheumatic drugs. *RMD Open*, 2019, 5, s. e000806.
- Strand, V. – Tundia, N. – Bergman, M., et al.: Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. *Rheumatology*, 2021, 60, s. 5583–5594.
- Tal Gonen, B. A. – Amital, H.: Cannabis and cannabinoids in the treatment of rheumatic diseases. *Rambam Maimonides Med J*, 2020, 11, s. e0007
- Tooth, I. – Juhasz, M. F. – Szabo, L., et al.: Janus kinase inhibitors improve disease activity and patients-reported outcomes in rheumatoid arthritis. *Int J Mol Sci*, 2022, 23, s. 1246–1267.
- Walitt, B. – Urrutia, G. – Nishihiniya, M. B., et al.: Selective serotonin reuptake inhibitors for fibromyalgia syndrome. *Cochrane Database Syst Rev*, 2015, 2015, s. CD011735.

## Certolizumab pegol ve vztahu k akutní přední uveitidě. Výsledky studie C-VIEW

MUDr. Kristýna Bubová, Ph.D. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

- Sieper, J. – Poddubnyy, D.: Axial spondyloarthritis. *Lancet*, 2017, 390, s. 73–84.
- Rudwaleit, M. – van der Heijde, D. – Landewe, R., et al.: The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- Cantini, F. – Nannini, C. – Cassarà, E., et al.: Uveitis in spondyloarthritis: an overview. *J Rheumatol Suppl*, 2015, 93, s. 27–29.
- D'Ambrosio, E. M. – La Cava, M. – Tortorella, P., et al.: Clinical features and complications of the HLA-B27-associated acute anterior uveitis: a meta-analysis. *Semin Ophthalmol*, 2017, 32, s. 689–701.
- Bengtsson, K. – Forsblad-d'Elia, H. – Deminger, A., et al.: Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. *Rheumatology*, 2021, 60, s. 2725–2734.
- Zeboulon, N. – Dougados, M. – Gossec, L.: Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. *Ann Rheum Dis*, 2008, 67, s. 955–959.
- Rosenbaum, J. T. – Bodaghi, B. – Couto, C., et al.: New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. *Semin Arthritis Rheum*, 2019, 49, s. 438–445.
- van der Horst-Bruinsma, I. E. – van Bentum, R. E. – Verbraak, F. D., et al.: Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. *Ther Adv Musculoskelet Dis*, 2021, 13, 1757920X211003803.

## Postavení adalimumabu v léčbě revmatických chorob

prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav, Praha

- Finckh, A. – Gilbert, B. – Hodkinson, B., et al.: Global epidemiology of rheumatoid arthritis. *Nat Rev Rheumatol*, 2022, 18, s. 591–602.
- Stolwijk, C. – van Onna, M. – Boonen, A., et al.: Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. *Arthritis Care Res*, 2016, 68, s. 1320–1331.
- Smolen, J. S. – Aletaha, D. – McInnes, I. B.: Rheumatoid arthritis. *Lancet*, 2016, 388, s. 2023–2038.
- Schett, G. – Rahman, P. – Ritchlin, C., et al.: Psoriatic arthritis from a mechanistic perspective. *Nat Rev Rheumatol*, 2022, 18, s. 311–325.
- Highlights of prescribing information. Dostupné z: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/125057s4061bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s4061bl.pdf), vyhledáno 21. 3. 2023.
- Tracey, D. – Klareskog, L. – Sasso, E. H., et al.: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther*, 2008, 117, s. 244–279.
- Mehta, P. – Manson, J. J.: What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis? *Front Immunol*, 2020, 11, s. 589.
- Weinblatt, M. E. – Keystone, E. C. – Furst, D. E., et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum*, 2003, 48, s. 35–45.
- Weinblatt, M. E. – Keystone, E. C. – Furst, D. E., et al.: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis*, 2006, 65, s. 753–759.
- Burmester, G. R. – Ferraccioli, G. – Flipo, R. M., et al.: Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. *Arthritis Rheum*, 2008, 59, s. 32–41.
- Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F., et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
- Keystone, E. C. – Kavanaugh, A. F. – Sharp, J. T., et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*, 2004, 50, s. 1400–1411.
- Emery, P. – Genovese, M. C. – van Vollenhoven, R., et al.: Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. *J Rheumatol*, 2009, 36, s. 1429–1441.
- Soubrier, M. – Puéchal, X. – Sibilia, J., et al.: Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology*, 2009, 48, s. 1429–1434.
- Kavanaugh, A. – van Vollenhoven, R. F. – Fleischmann, R., et al.: Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumor necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. *Ann Rheum Dis*, 2018, 77, s. 289–292.
- Smolen, J. S. – Burmester, G. R. – Combe, B., et al.: Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. *Lancet*, 2016, 388, s. 2763–2774.
- Smolen, J. S. – Landewé, R. B. M. – Bergstra, S. A., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis*, 2023, 82, s. 3–18.
- Mease, P. J. – Gladman, D. D. – Ritchlin, C. T., et al.: Adalimumab effectiveness in psoriatic arthritis trial study group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*, 2005, 52, s. 3279–3289.
- Gladman, D. D. – Mease, P. J. – Ritchlin, C. T., et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis Rheum*, 2007, 56, s. 476–488.
- Van den Bosch, F. – Manger, B. – Goupille, P., et al.: Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. *Ann Rheum Dis*, 2010, 69, s. 394–399.
- Landewé, R. – Ritchlin, C. T. – Aletaha, D., et al.: Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. *Rheumatology*, 2019, 58, s. 1025–1033.
- Haibel, H. – Rudwaleit, M. – Brandt, H. C., et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. *Arthritis Rheum*, 2006, 54, s. 678–681.
- van der Heijde, D. – Kivitz, A. – Schiff, M. H., et al.: ATLAS Study Group: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
- van der Heijde, D. – Schiff, M. H. – Sieper, J., et al.: ATLAS Study Group: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. *Ann Rheum Dis*, 2009, 68, s. 922–929.
- Rudwaleit, M. – Claudepierre, P. – Wordsworth, P., et al.: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. *J Rheumatol*, 2009, 36, s. 801–808.
- Rudwaleit, M. – Van den Bosch, F. – Kron, M., et al.: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. *Arthritis Res Ther*, 2010, 12, s. R17.
- van der Heijde, D. – Salonen, D. – Weissman, B. N., et al.: Canadain (M03-606) study group; ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. *Arthritis Res Ther*, 2009, 11, s. R127.
- Torgutalp, M. – Rios Rodriguez, V. – Dilbaryan, A., et al.: Treatment with tumor necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis. *Ann Rheum Dis*, 2022, 81, s. 1252–1259.
- Rudwaleit, M. – Rødevand, E. – Holck, P., et al.: Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. *Ann Rheum Dis*, 2009, 68, s. 696–701.
- Sieper, J. – van der Heijde, D. – Dougados, M., et al.: Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis*, 2013, 72, s. 815–822.
- Sieper, J. – Landewé, R. – Magrey, M. – Anderson, J. K., et al.: Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. *RMD Open*, 2019, 5, s. e000917.
- Mease, P. – Sieper, J. – Van den Bosch, F., et al.: Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. *Arthritis Rheumatol*, 2015, 67, s. 914–923.
- Minozzi, S. – Bonovas, S. – Lytras, T., et al.: Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. *Expert Opin Drug Saf*, 2016, 15, suppl. 1, s. 11–34.

- 34 Nard, F. D. – Todoerti, M. – Grosso, V., et al.: Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biological treatment: Extending perspective from old to newer drugs. *World J Hepatol*, 2015, 7, s. 344–361.
- 35 Blyszczuk, P. – Szekanez, Z.: Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. *RMD Open*, 2020, 6, s. e001032
- 36 Jani, M. – Dixon, W. G. – Chinoy, H.: Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. *Rheumatology*, 2018, 57, s. 1896–1907.
- 37 Cassone, G. – Manfredi, A. – Vacchi, C., et al.: Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. *J Clin Med*, 2020, 9, s. 1082.
- 38 Regierer, A. C. – Strangfeld, A.: Rheumatoid arthritis treatment in patients with a history of cancer. *Curr Opin Rheumatol*, 2018, 30, s. 288–294.
- 39 Mercer, L. K. – Asking, J. – Raaschou, P., et al.: Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. *Ann Rheum Dis*, 2017, 76, s. 386–391.
- 40 Bessissow, T. – Renard, M. – Hoffman, I., et al.: Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. *Aliment Pharmacol Ther*, 2012, 36, s. 312–323.
- 41 Schreiber, S. – Puig, L. – Gonçalves, J., et al.: Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases. *Semin Arthritis Rheum*, 2022, 55, s. 152023.
- 42 Colloca, L. – Panaccione, R. – Murphy, T. K.: The clinical implications of nocebo effects for biosimilar therapy. *Front Pharmacol*, 2019, 10, s. 1372.
- 43 Yoo, D. H. – Hrycaj, P. – Miranda, P., et al.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. *Ann Rheum Dis*, 2013, 72, s. 1613–1620.
- 44 Cohen, S. – Genovese, M. C. – Choy, E., et al.: Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. *Ann Rheum Dis*, 2017, 76, s. 1679–1687.
- 45 Fleischmann, R. – Lakhnani, S. – Saikali, W., et al.: Multiple switching between the biosimilar adalimumab PF-06410293 (Abrilada) and reference adalimumab (Humira) in combination with methotrexate in patients with moderately to severely active rheumatoid arthritis [abstract]. *Arthritis Rheumatol*, 2022, 74, suppl. 9.
- 46 Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2022. Dostupné z: [https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu\\_en.pdf](https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf), vyhledáno 21. 3. 2023.

## Bolest a její ovlivnění u spondyloartritid

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie, Fakultní nemocnice v Plzni

- 1 Pavelka, K.: Bolest u zánětlivých revmatických onemocnění. *Farmakoterapie*, 2022, 18, s. 700–709.
- 2 Pavelka, K. – Rovenský, J.: *Klinická revmatologie*. Praha, Galén, 2003.
- 3 Pavelka, K. – Šenolt, L. – Šedová, L., et al.: *Spondyloartritidy*. Praha, Maxdorf, 2020, s. 123–129.
- 4 Rudwaleit, M. – Landewé, R. – van der Heijde, D., et al.: The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis*, 2009, 68, s. 770–776.
- 5 Deodhar, A. – Strand, V. – Conaghan, P. G., et al.: Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy: results from a large multinational real-world study. *BMC Rheumatol*, 2020, 4, s. 19.
- 6 Strand, V. – Deodhar, A. – Rieke, A., et al.: Pain and fatigue in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: multinational real-world findings. *J Clin Rheumatol*, 2021, 27, s. e446–e455.
- 7 Conaghan, P. G. – Alten, R. – Deodhar, A., et al.: Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. *RMD Open*, 2020, 6, s. e001240.
- 8 Ribbjerg-Madsen, S. – Christensen, A. W. – Christensen, R., et al.: Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. *PLoS ONE*, 12(7): e0180014.
- 9 Pongratz, G.: Schmerz bei rheumatischen Erkrankungen. Was haben Biologika Januskinase Inhibitoren zu bieten? *Rheumatol*, 2021, 80, s. 214–225.
- 10 de Vlam, K. – Gallo, G. – Mease, P. J., et al.: Ixekizumab shows a distinct pattern of pain improvement beyond inflammation in radiographic axial spondyloarthritis. *Ann Rheum Dis*, 2021, 80, s. 707–708.
- 11 de Vlam, K. – Gallo, G. – Mease, P., et al.: Ixekizumab shows a pattern of pain improvement in patients with and without measurable inflammation in psoriatic arthritis [abstract]. *Arthritis Rheumatol*, 2021, 73, suppl. 9, s. 2791–2793.

## Pacient s těžkou formou alopecia areata dosahuje rychlého růstu vlasů po léčbě baricitinibem – kazuistika

MUDr. PharmDr. Athanasios J. Stefanis Dermatovenerologická klinika 3. LF UK a Fakultní nemocnice Královské Vinohrady, Praha

- 1 King, B. – Mostaghimi, A. – Shimomura, Y., et al.: Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. *Br J Dermatol*, 2023, 188, s. 218–227.
- 2 King, B. – Ohshima, M. – Kwon, O., et al.: BRAVE-AA Investigators: Two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med*, 2022, 386, s. 1687–1699.
- 3 Lee, H. H. – Gwillim, E. – Patel, K. R., et al.: Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. *J Am Acad Dermatol*, 2020, 82, s. 675–682.
- 4 Senna, M. – Ko, J. – Tosti, A., et al.: Alopecia areata treatment patterns, healthcare resource utilization, and comorbidities in the US population using insurance claims. *Adv Ther*, 2021, 38, s. 4646–4658.
- 5 Stefanis, A. J.: Janus Kinase inhibitors in the treatment of alopecia areata. *Prague Med Rep*, 2023, 124, s. 5–15.
- 6 Stefanis, A. J. – Arenberger, P. – Arenbergerova, M. – Gkalpakiotis, S.: Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment. *Br J Dermatol*, 2021, 185, s. 847–849.
- 7 Villasante Fricke, A. C. – Miteva, M.: Epidemiology and burden of alopecia areata: a systematic review. *Clin Cosmetol Invest Dermatol*, 2015, 8, s. 397–403.
- 8 Zhou, C. – Li, X. – Wang, C., et al.: Alopecia areata: an update on etiology, pathogenesis, diagnosis, and management. *Clin Rev Allergy Immunol*, 2021, 61, s. 403–423.

## Přehled současných možností léčby roztroušené sklerózy

MUDr. Radek Ampapa Centrum pro léčbu demyelinizačních onemocnění, Neurologické oddělení Nemocnice Jihlava

- 1 Filippi, M. – Bar-Or, A. – Piehl, F., et al.: Multiple sclerosis. *Nat Rev Dis Primers*, 2018, 4, s. 43.
- 2 Browne, P. – Chandraratna, D. – Angood, C., et al.: Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. *Neurology*, 2014, 83, s. 1022–1024.
- 3 Lublin, F. D. – Reingold, S. C.: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. *Neurology*, 1996, 46, s. 907–911.
- 4 Lublin, F. D.: New multiple sclerosis phenotypic classification. *Eur Neurol*, 2014, 72 suppl. 1, s. 1–5.
- 5 Smith, A. L. – Cohen, J. – Hua, L. H.: Therapeutic targets for multiple sclerosis: current treatment goals and future directions. *Neurotherapeutics*, 2017, 14, s. 952–960.
- 6 Simpson, A. – Mowry, E. M. – Newsome, S. D.: Early aggressive treatment approaches for multiple sclerosis. *Curr Treat Options Neurol*, 2021, 23, s. 19.
- 7 Ruggieri, S. – Pontecorvo, S. – Tortorella, C., et al.: Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. *Mult Scler Demyelinating Disord*, 2018, 3, s. 5.
- 8 Thompson, A. J. – Banwell, B. L. – Barkhof, F., et al.: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*, 2018, 17, s. 162–173.
- 9 Hellwig, K. – Geissbuehler, Y. – Sabido, M., et al.: Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. *J Neurol*, 2020, 267, s. 1715–1723.
- 10 Sandberg-Wollheim, M. – Neudorfer, P. – Grinspan, A., et al.: Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. *Int JMS Care*, 2018, 20, s. 9–14.
- 11 Bar-Or, A. – Pachner, A. – Menguy-Vacheron, F., et al.: Teriflunomide and its mechanism of action in multiple sclerosis. *Drugs*, 2014, 74, s. 659–674.
- 12 McGinley, M. P. – Cohen, J. A.: Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. *Lancet*, 2021, s. 1184–1194. doi.org/10.1016/S0140-6736(21)00244-0.
- 13 Landi, D. – Bovis, F. – Grimaldi, A., et al.: Exposure to natalizumab through out pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. *J Neurol Neurosurg Psychiatr*, 2022, 93, s. 1306–1316.
- 14 García-Merino, A.: Bruton's tyrosine kinase inhibitors: a new generation of promising agents for multiple sclerosis therapy. *Cells*, 2021, 10, s. 2560.

## Biologická léčba astmatu

MUDr. Alena Vlachová | doc. MUDr. Libor Fila, Ph.D. Pneumologická klinika 2. LF UK a FN v Motole, Praha

- 1 Teřl, M. – Sedláč, V. – Krčmář, I.: Doporučený postup diagnostiky a léčby těžkého astmatu. Odesílání pacientů do center. *Stud Pneumol Phthiseol*, 2022, 82, s. 122–127.
- 2 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Dostupné z: <https://ginasthma.org/gina-reports/>, vyhledáno 10. 3. 2023.
- 3 Xolair, SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0025447&tab=texts>, vyhledáno 14. 2. 2023
- 4 Nucala, SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0209057&tab=texts>, vyhledáno 14. 2. 2023
- 5 Fasena, SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0222689&tab=texts>, vyhledáno 14. 2. 2023
- 6 Cinqair, SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0209485&tab=texts>, vyhledáno 14. 2. 2023
- 7 Dipuxent, SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0222560&tab=texts>, vyhledáno 14. 2. 2023
- 8 Pauk, N.: Tezepelumab: nadějná budoucnost pro pacienty s těžkým astmatem. *Farmakoterapie*, 2022, 18, s. 484–488.
- 9 Pauk, N.: Dlouhodobá léčba astmatu. *Acta Medicinæ*, 2022, 11, s. 55–58.
- 10 Corren, J. – Parnes, J. R. – Wang, L., et al.: Tezepelumab in adults with

- uncontrolled asthma. *N Engl J Med*, 2017, 377, s. 936–946.
- 11 Chan R. – Stewart, K. – Misirovs, R., et al.: Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. *Allergy Clin Immunol Pract*, 2022, 10, s. 1497–1505.
- 12 Porsbjerg, C. M. – Sverriid, A. – Lloyd, C. M., et al.: Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. *Eur Respir J*, 2020, 56, s. 2000260.
- 13 Gauvreau, G. M. – Sehmi, R. – Ambrose, Ch. S., et al.: Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. *Expert Opin Ther Targets*, 2020, 24, s. 777–792.
- 14 Wechsler, M. E., et al.: Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. *N Engl J Med*, 2021, 385, s. 1656–1668.
- 15 Marone, M. – Spadaro, G. – Braile, M., et al.: Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. *Expert Opin Investig Drug*, 2019, 28, s. 931–940.

## Současné možnosti léčby autozomálně dominantní polycystické choroby ledvin

doc. MUDr. Jana Reiterová, Ph.D. Klinika nefrologie 1. LF UK a VFN v Praze

- 1 Lanktree, M. B. – Haghighi, A. – Guiard, E., et al.: Prevalence estimates of polycystic kidney and liver disease by population sequencing. *J Am Soc Nephrol*, 2018, 29, s. 2593–2600.
- 2 Schrier, R. W. – Abebe, K. – Perrone, R. D., et al.: Blood pressure in early autosomal dominant polycystic kidney disease. *N Engl J Med*, 2014, 371, s. 2255–2266.
- 3 Torres, V. E. – Chapman, A. B. – Devuyst, O., et al.: Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med*, 2012, 367, s. 2255–2266.
- 4 Torres, V. E. – Chapman, A. B. – Devuyst, O., et al.: Tolvaptan in later-stage autosomal dominant polycystic kidney disease. *N Engl J Med*, 2017, 377, s. 1930–1943.
- 5 Caroli, A. – Perico, N. – Perna, A., et al.: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomized, placebo controlled, multicentre trial. *Lancet*, 2013, 383, s. 1485–1495.
- 6 Meijer, E. – Visser, F. W. – van Aerts, R. M. M., et al.: Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. *JAMA*, 2018, 320, s. 2010–2019.
- 7 Cadnapaphornchai, M. A. – George, D. M. – McFann, K., et al.: Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*, 2014, 9, s. 889–896.
- 8 Yanda, M. K. – Liu, Q. – Cebotaru, L. A., et al.: Potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector. *J Biol Chem*, 2018, 293, s. 11513–11526.
- 9 Perrone, R. D. – Abebe, K. Z. – Watnick, T. J., et al.: Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). *Kidney Int*, 2021, 100, s. 684–696.
- 10 Tesar, V. – Ciechanowski, K. – Pei, Y., et al.: Bosutinib versus placebo for autosomal dominant polycystic kidney disease. *J Am Soc Nephrol*, 2017, 28, s. 3404–3413.